<div id="readability-page-1"><p>4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) was down 5.3% during mid-day trading on Tuesday . The company traded as low as $10.53 and last traded at $10.4930. Approximately 523,751 shares were traded  during mid-day trading, a decline of 39% from the average daily volume of 852,534 shares. The stock had previously closed at $11.08.</p><h2>Analyst Upgrades and Downgrades</h2><p>Several research analysts have issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, November 11th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Roth Capital decreased their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, August 12th. Morgan Stanley raised 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a research note on Friday, November 7th. Finally, Leerink Partners  restated an &#34;outperform&#34; rating and set a $17.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Eight research analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $28.70.</p><p><b>Read Our Latest Report on FDMT</b></p><h2>4D Molecular Therapeutics Price Performance</h2><p>The stock's fifty day simple moving average is $10.43 and its two-hundred day simple moving average is $7.13. The company has a market capitalization of $600.15 million, a price-to-earnings ratio of -2.79 and a beta of 2.96. </p><p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.40 million.  On average, sell-side analysts predict that  4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year. </p><h2>Insider Transactions at 4D Molecular Therapeutics</h2><p>In related news, insider Scott Bizily sold 2,678 shares of the firm's stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the sale, the insider directly owned 3,594 shares in the company, valued at approximately $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 10,763 shares of company stock worth $109,415 over the last quarter. 9.60% of the stock is owned by insiders. </p><h2>Institutional Investors Weigh In On 4D Molecular Therapeutics</h2><p>Large investors have recently added to or reduced their stakes in the stock. Wexford Capital LP bought a new position in shares of  4D Molecular Therapeutics during the 3rd quarter worth about $41,000.  Farther Finance Advisors LLC lifted its holdings in  4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter.  Abich Financial Wealth Management LLC acquired a new position in shares of  4D Molecular Therapeutics in the 3rd quarter worth approximately $80,000.  Inscription Capital LLC acquired a new position in  4D Molecular Therapeutics in the third quarter worth $94,000.  Finally, Impact Partnership Wealth LLC bought a new stake in shares of  4D Molecular Therapeutics during the third quarter worth $96,000. Institutional investors own  99.27% of the company's stock. </p><h2>4D Molecular Therapeutics Company Profile</h2> (Get Free Report)<p>4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than 4D Molecular Therapeutics</li><li>ETF Screener: Uses and Step-by-Step Guide </li><li>Office Suite Gets Pricier: Microsoft’s Bold Move Comes With Risk</li><li>What is a Special Dividend?</li><li>Big Blue’s Big Bet: IBM Buys AI Nervous System for $11B</li><li>How to Effectively Use the MarketBeat Ratings Screener</li><li>Carvana Soars Over 10,000% From Lows—Now It’s in the S&amp;P 500</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

FDMT

<p>4D Molecular Therapeutics (NASDAQ:FDMT) stock fell 5.3% during mid-day trading, with a significant drop in trading volume. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a target price of $28.70. The company reported a quarterly EPS of ($1.01), slightly better than expected. Insider transactions and institutional investments are notable, with insiders owning 9.60% of the stock.</p>

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 5.3% - Here's Why